Pharming Group (NASDAQ:PHAR) Releases Earnings Results, Beats Expectations By $0.05 EPS

Pharming Group (NASDAQ:PHAR) released its quarterly earnings results on Thursday. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.05 by $0.05, Zacks reports. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The business had revenue of $97.30 million for the quarter, compared to the consensus estimate of $98.22 million. Pharming Group updated its FY 2025 guidance to EPS.

Pharming Group Price Performance

PHAR opened at $14.70 on Friday. The company has a quick ratio of 2.07, a current ratio of 2.79 and a debt-to-equity ratio of 0.38. The company’s 50-day moving average price is $14.29 and its 200 day moving average price is $11.95. Pharming Group has a fifty-two week low of $7.31 and a fifty-two week high of $17.08. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -113.08 and a beta of 0.03.

Analysts Set New Price Targets

PHAR has been the topic of several recent research reports. Weiss Ratings raised shares of Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a report on Saturday, October 25th. Zacks Research cut Pharming Group from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 30th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $30.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC bought a new position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,979 shares of the company’s stock, valued at approximately $32,000. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.